Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Viamet Pharmaceuticals and National Institutes of Health (NIH) have decided to co-develop Viamet's oral antifungal agent to treat cryptococcal meningitis.
Subscribe to our email newsletter
Additionally, NIH has selected Viamet’s novel antifungal compounds for inclusion in the National Institutes of Health’s (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program.
Viamet president and CEO Robert Schotzinger said to be one of only four projects selected for funding is a further validation of Viamet’s Metallophile Technology.
"The Viamet compound selected for inclusion in the TRND program has shown superior efficacy in advanced animal models of cryptococcal meningitis when compared to standard therapies," Schotzinger said.